Koroshetz W J, Moskowitz M A
Stroke Service, Massachusetts General Hospital, Boston 02114, USA.
Trends Pharmacol Sci. 1996 Jun;17(6):227-33. doi: 10.1016/0165-6147(96)10020-1.
Ischaemic stroke causes loss of brain function in millions of people worldwide each year. Despite the enormity of the problem, no currently approved therapy reduces stroke size or neurological disability. This contrasts with a number of recently developed agents, reviewed here by Walter Koroshetz and Michael Moskowitz, which limit infarct size in animal stroke models. Therapies that dissolve clot and restore blood flow, block excitatory neurotransmission, prevent the ischaemic inflammatory response or scavange free radicals have the potential to revolutionize stroke treatment if proven beneficial in ongoing, placebo-controlled clinical trials. Developments in the experimental arena continue to reinforce the need to characterize the pathophysiological stages leading to brain infarction and recovery.
缺血性中风每年在全球导致数百万人脑功能丧失。尽管该问题严重，但目前尚无获批疗法能缩小中风面积或减轻神经功能障碍。这与沃尔特·科罗谢茨和迈克尔·莫斯科维茨在此回顾的一些最近开发的药物形成对比，这些药物在动物中风模型中可限制梗死面积。溶解血栓并恢复血流、阻断兴奋性神经传递、预防缺血性炎症反应或清除自由基的疗法，如果在正在进行的安慰剂对照临床试验中被证明有益，就有可能彻底改变中风治疗。实验领域的进展不断强化了对导致脑梗死和恢复的病理生理阶段进行特征描述的必要性。
